Israel - English - Ministry of Health

teva medical marketing ltd. - water for injections - solvent for parenteral use - water for injections 3000 ml - other i.v. solution additives - indicated in the aseptic preparation of parenteral admixtures.

Israel - English - Ministry of Health

teva medical marketing ltd. - glucose monohydrate; sodium chloride - solution for infusion - glucose monohydrate 5 g / 100 ml; sodium chloride 0.33 g / 100 ml - electrolytes - electrolytes - a source of water, electrolytes and calories.

Israel - English - Ministry of Health

teva medical marketing ltd. - calcium chloride; lactic acid as sodium; potassium chloride; sodium chloride - solution for injection - sodium chloride 6 g/l; potassium chloride 0.3 g/l; calcium chloride 0.2 g/l; lactic acid as sodium 3.1 g/l - electrolytes with carbohydrates - electrolytes with carbohydrates - as a supply of water, for administration of electrolytes or calories, or as an alkalinizing agent.

Israel - English - Ministry of Health

teva medical marketing ltd. - glucose as monohydrate - solution for infusion - glucose as monohydrate 20 g / 100 ml - glucose - glucose - dextrose injection is indicated as a caloric compnent in parenteral nutrition regimen. it is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot/should not be used 2) gastrointestinal absorption of protein is impaired or 3) metabolic requirement sfor protein are substantially increases as extensive burns.

Israel - English - Ministry of Health

teva medical marketing ltd. - citric acid anhydrous; glucose as monohydrate; sodium citrate - solution - citric acid anhydrous 730 mg / 100 ml; sodium citrate 2.2 g / 100 ml; glucose as monohydrate 2.45 g / 100 ml - glucose - glucose - for use with cytapheresis device only.

Israel - English - Ministry of Health

teva medical marketing ltd. - sodium chloride 9 mg/ml - solution for infusion - sodium chloride - a source of water and electrolytes. also indicated for use as a priming solution in hemodialysis procedures.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - repaglinide - tablets - repaglinide 0.5 mg - repaglinide - repaglinide - treatment of type ii diabetes.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - repaglinide - tablets - repaglinide 1 mg - repaglinide - repaglinide - treatment of type ii diabetes.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - tablets - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute c

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - tablets - pravastatin sodium 20 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute co